Sign in to view content

Progression of diabetic retinopathy in patients treated with 0.2 μg/day

Raymond Iezzi, MD, MS

Video
Published 2017

Related

Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody RG7716 in Diabetic Macular Edema: 36-Week Results From the Phase 2 BOULEVARD Clinical Trial
Rishi P. Singh, MD
Annual Meeting Talks
2018
Phase 2a Study of CU06-1004, an Oral Endothelial Dysfunction Blocker For the Treatment of Diabetic Macular Edema (DME)
Victor Hugo Gonzalez, MD
Annual Meeting Talks
2024
Diabetic Retinopathy 1 Symposium
Annual Meeting Talks
2020

Category: Diabetic Retinopathy

See more